Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Piper Sandler Maintains Neutral on Itron, Raises Price Target to $58

Piper Sandler analyst Kashy Harrison maintains Itron (NASDAQ:ITRI) with a Neutral and raises the price target from $48 to $58.

byBenzinga Newsdesk

February 28, 2023

1 minute read

Piper Sandler analyst Kashy Harrison maintains Itron (NASDAQ:ITRI) with a Neutral and raises the price target from $48 to $58.

Liminal BioSciences Subsidiary, Prometic Biotherapeutics Inc., Sells Rare Pediatric Disease Priority Review Voucher For $105M

By Bill Haddad

August 9, 7:33 AM

Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a Liminal BioSciences Inc.

LMNL

Vontier Q1 EPS $0.70 Beats $0.66 Estimate, Sales $748.10M Beat $728.26M Estimate

By Benzinga Newsdesk

May 5, 6:08 AM

Vontier (NYSE:VNT) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.66 by 6.06 percent. This is a 11.11 percent increase over earnings of $0.63 per share from the same period

VNT